1. AHRO : Austin Health Research Online

Thomas John

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Thomas John
Full Name
John, Thomas
 
Variants
John, Tom
 
Department
 
Personal Site
https://www.onjcancercentre.org/profile/a-prof.-tom-john
 
ORCID
Loading... 3 0 20 0 false

Publications

Results 21-40 of 112 (Search time: 0.01 seconds).

Publication YearTitleAuthor(s)
2116-Aug-2021Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.Murali, Krithika; Dwarte, Tanya M; Nikfarjam, Mehrdad ; Tucker, Katherine M; Vaughan, Rhys B ; Efthymiou, Marios ; Collins, Allison L ; Spigelman, Allan D; Salmon, Lucinda ; Johns, Amber L; Williams, David B; Delatycki, Martin B ; John, Thomas ; Stoita, Alina
2215-Jun-2021Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas 
2328-May-2021A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Jenkins, Laura J; Poh, Ashleigh R; Walkiewicz, Marzena; Leong, Trishe; Mariadason, John M ; Cebon, Jonathan S ; Balachander, Srividya B; Cidado, Justin R; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas 
24Apr-2021The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.Arulananda, Surein; Lee, Erinna F; Fairlie, Walter Douglas ; John, Thomas 
25Mar-2021Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.Chia, Puey Ling ; Parakh, Sagun ; Russell, Prudence; Gan, Hui K ; Asadi, Khashayar ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Liu, Zhanqi; Thapa, Bibhusal ; Scott, Fiona E; Scott, Andrew M ; John, Thomas 
26Feb-2021First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; Lingua, Alejo; Salman, Pamela; Souquet, Pierre-Jean; De Marchi, Pedro; Martin, Claudio; Pérol, Maurice; Scherpereel, Arnaud; Lu, Shun; John, Thomas ; Carbone, David P; Meadows-Shropshire, Stephanie; Agrawal, Shruti; Oukessou, Abderrahim; Yan, Jinchun; Reck, Martin
272021Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.Balasubramanian, Adithya ; Onggo, James; Gunjur, Ashray ; John, Thomas ; Parakh, Sagun 
28Dec-2020Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.Chia, Puey Ling ; Russell, Prudence; Asadi, Khashi; Thapa, Bibhusal ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Eriksson, Ulf; Scott, Andrew M ; John, Thomas 
2926-Nov-2020The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.Arulananda, Surein; Lee, Erinna F; Fairlie, W Douglas; John, Thomas 
30Nov-2020Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.Papadimitrakopoulou, V A; Mok, T S; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, Thomas ; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, Y-L
3131-Oct-2020BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas 
322-Oct-2020Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.Chia, Puey Ling ; Parakh, Sagun ; Tsao, Ming-Sound; Pham, Nhu-An; Gan, Hui K ; Cao, Diana; Burvenich, Ingrid J G; Rigopoulos, Angela; Reilly, Edward B; John, Thomas ; Scott, Andrew M 
33Oct-2020Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate.Anderson, Mark G; Falls, Hugh D; Mitten, Michael J; Oleksijew, Anatol; Vaidya, Kedar S; Boghaert, Erwin R; Gao, Wenqing; Palma, Joann P; Cao, Diana; Chia, Puey Ling ; John, Thomas ; Gan, Hui K ; Scott, Andrew M ; Reilly, Edward B
34Oct-2020Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Wu, Yi-Long; Tsuboi, Masahiro; He, Jie; John, Thomas ; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun; Lee, Kye-Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Zeng, Lingmin; Hodge, Rachel; Atasoy, Ajlan; Rukazenkov, Yuri; Herbst, Roy S
35Sep-2020Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.Nowak, Anna K; Lesterhuis, W Joost; Kok, Peey-Sei; Brown, Chris; Hughes, Brett Gm; Karikios, Deme J; John, Thomas ; Kao, Steven C-H; Leslie, Connull; Cook, Alistair M; Pavlakis, Nick; Briscoe, Karen; O'Byrne, Kenneth J; Karapetis, Christos S; Lam, Wei-Sen; Langford, Ailsa; Yip, Sonia; Stockler, Martin R
36Sep-2020Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.McClure, Tess ; Cui, Wanyuan; Asadi, Khashayar ; John, Thomas ; Testro, Adam G 
37Aug-2020NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.Leal, Jose Luis; Peters, Geoffrey; Szaumkessel, Marcin; Leong, Trishe Y-M; Asadi, Khashayar ; Rivalland, Gareth; Do, Hongdo; Senko, Clare ; Mitchell, Paul L R ; Quing, Chai Zi; Dobrovic, Alexander ; Thapa, Bibhusal ; John, Thomas 
38Jun-2020Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.Brockwell, Natasha K; Alamgeer, Muhammad; Kumar, Beena; Rivalland, Gareth; John, Thomas ; Parker, Belinda S
39Apr-2020Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report.Lie, Gabrielle ; Weickhardt, Andrew; Kearney, Leighton G ; Lam, Que; John, Thomas ; Liew, David F L ; Arulananda, Surein
40Mar-2020Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.Felip, Enriqueta; de Braud, Filippo G; Maur, Michela; Loong, Herbert H; Shaw, Alice Tsang; Vansteenkiste, Johan F; John, Thomas ; Liu, Geoffrey; Lolkema, Martijn P; Selvaggi, Giovanni; Giannone, Vanessa; Cazorla, Pilar; Baum, Jason; Balbin, O Alejandro; Wang, Luojun Victor; Lau, Yvonne Y; Scott, Jeffrey W; Tan, Daniel Shao-Weng